早期肝细胞癌接受90钇经动脉放射栓塞后PD-1表达的谱系特异性调控及其对治疗结局的影响
本研究前瞻性纳入99例接受首周期90钇放射栓塞作为肝移植桥接/降期的肝细胞癌患者,通过流式细胞术分析治疗前后PD-1表达动态。结果显示,CD8+ T细胞PD-1上调与肿瘤进展及无进展时间缩短相关,而治疗相关淋巴细胞减少与治疗反应或进展风险无关。
要点
- CD8+ T细胞PD-1上调与肝细胞癌进展风险增加及无进展时间缩短相关。
- 90钇治疗后淋巴细胞显著下降(P < 0.001),但与PD-1表达及无进展时间无关。
- 治疗相关淋巴细胞减少未影响治疗反应或短期进展风险。
核心结论
- 外周T细胞PD-1表达升高与接受首周期90钇桥接/降期至肝移植的肝细胞癌患者进展风险增加及无进展时间缩短相关。
- 治疗诱导的淋巴细胞减少与治疗反应或进展风险增加无关,提示这一预期不良事件不影响肝细胞癌短期结局。
研究设计与样本
- 前瞻性纳入99例接受首周期90钇作为肝移植桥接的肝细胞癌患者。
- 在90钇治疗前及常规影像随访期间采集血液标本,通过流式细胞术分析PD-1表达。
- 采用mRECIST标准评估完全缓解率(CR)和客观缓解率(ORR)。
主要发现
- 在84/88例有可评估随访影像的患者中,局部ORR为83%,局部CR为63%;总ORR为71%,总CR为54%。
- 90钇治疗后CD8+ T细胞PD-1上调与肝细胞癌进展及无进展时间缩短相关。
- 90钇治疗与治疗后淋巴细胞显著下降相关(P < 0.001),该下降独立于CD4+或CD8+ T细胞的PD-1表达(P = 0.751和P = 0.375),且与无进展时间风险无关。
- 淋巴细胞变化与治疗后PD-1表达及无进展时间均不相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Liver-directed therapies, including 90Yttrium (90Y) radioembolization, play an integral role in the management of HCC with excellent response rates. This has led to clinical trials of immunotherapy in combination with 90Y. Elevated PD-1 expression and lymphopenia were recently shown as risk factors for disease progression in early-stage HCC treated with liver-directed therapies. The aim of this study was to investigate PD-1 expression dynamics in bridge/downstage to transplant in HCC patients receiving first-cycle 90Y and evaluate the impact of these changes on response rates and time-to-progression (TTP). METHODS: Patients with HCC receiving first-cycle 90Y as a bridge to liver transplantation (n = 99) were prospectively enrolled. Blood specimens were collected before 90Y and again during routine imagining follow-up to analyze PD-1 expression via flow cytometry. Complete and objective response rates (CR and ORR) were determined using mRECIST. RESULTS: In 84/88 patients with available follow-up imaging, 83% had a localized ORR with 63% having localized CR. For overall response, 71% and 54% experienced ORR and CR, respectively. Post-90Y PD-1 upregulation in CD8 + associated with HCC progression and decreased TTP. Treatment with 90Y was associated with an anticipated significant post-treatment drop in lymphocytes (P < 0.001) that was independent of PD-1 expression for either CD4+ or CD8+ T cells (P = 0.751 and P = 0.375) and not associated with TTP risk. The change in lymphocytes was not correlated with PD-1 expression following treatment nor TTP. CONCLUSIONS: Elevated PD-1 expression on peripheral T cells is associated with increased risk of HCC progression and shorter time to progression in bridging/downstaging to transplant HCC patients undergoing first-cycle 90Y. Treatment-induced lymphopenia was not associated with treatment response, or increased progression risk, suggesting this anticipated adverse event does not impact short-term HCC outcomes.
引用
- Núñez KG, Sandow T, Gimenez J, et al. Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes. Eur J Cancer. 2023. PMID: 37988841. doi:10.1016/j.ejca.2023.113442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。